Signatures associated with homologous recombination deficiency and immune regulation to improve clinical outcomes in patients with lung adenocarcinoma

PARP inhibitors can be used to treat solid tumors that often have mutations in important homologous recombination (HR) genes, such as BRCA1/2. While other kinds of tumors could also experience HR deficiencies, including those associated with lung cancer, there is little information on the frequency...

Descripción completa

Detalles Bibliográficos
Autores principales: Shang, Xueqian, Qi, Kang, Liu, Xiangzheng, Liu, Qinghao, Zhang, Xining, Wang, Dongliang, Huang, Weiming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562462/
https://www.ncbi.nlm.nih.gov/pubmed/36249053
http://dx.doi.org/10.3389/fonc.2022.854999

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562462/
https://www.ncbi.nlm.nih.gov/pubmed/36249053
http://dx.doi.org/10.3389/fonc.2022.854999

Ejemplares similares